Loading...
Uploaded by pharmapricing on Mar 27, 2011
Longitudinal pharma pricing analysis of global Nexavar revenues following FDA approval of treatment for heptacellular carcinoma, in 1Q08, using Pfizer's Sutent as a historical control.
Science & Technology
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)